Cabaletta has been evaluating the CAR-T, called resecabtagene autoleucel or rese-cel , across six so-called RESET studies ...

Recent innovations include engineering CAR T-cells to overcome the immunosuppressive tumour microenvironment and enhancing ...

FDA meeting to align on myositis registrational trial designs for rese-cel in 1H25 on track –– Enrolling approximately one patient per week ...

myositis, vasculitis, and myasthenia gravis; the expected cost associated with and impact of the restructuring; and Nkarta’s expected cash runway. Because such statements are subject to risks and ...

In January 2025, Cabaletta announced the first juvenile myositis clinical site in the ... evaluating rese-cel in patients with myasthenia gravis. In January 2025, Cabaletta announced the ...

Nkarta's NKX019 offers hope for autoimmune treatment. Upcoming trial data and strategic moves could fuel recovery. Read more ...

Corient Private Wealth LLC grew its holdings in shares of argenx SE (NASDAQ:ARGX – Free Report) by 14.7% in the 4th quarter, according to the company in its most recent 13F filing with the Securities ...

myositis, vasculitis, and myasthenia gravis; the expected cost associated with and impact of the restructuring; and Nkarta’s expected cash runway. Because such statements are subject to risks ...

That equation led Vyvgart, argenx’s treatment for generalized myasthenia gravis (gMG), to take the ... Argenx continues to study Vyvgart in myositis and thyroid eye disease and has secured ...

PHILADELPHIA, PA — Cabaletta Bio, Inc. (Nasdaq: CABA) has announced its financial results for the fourth quarter and full ...